Cargando…

A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients

The advanced-generation, broad-spectrum, intravenous (IV) cephalosporin, ceftobiprole, is an effective and well-tolerated treatment for adults with hospital-acquired pneumonia (HAP) or community-acquired pneumonia (CAP), but its effects in pediatric patients have not been established. METHODS: In th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bosheva, Miroslava, Gujabidze, Rusudan, Károly, Éva, Nemeth, Agnes, Saulay, Mikael, Smart, Jennifer I., Hamed, Kamal A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Antimicrobial Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104010/ https://www.ncbi.nlm.nih.gov/pubmed/33480665 http://dx.doi.org/10.1097/INF.0000000000003077

Ejemplares similares

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
por: Scheeren, Thomas W. L., et al.
Publicado: (2019)

Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)
por: Overcash, J Scott, et al.
Publicado: (2020)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents
por: Syriopoulou, Vassiliki, et al.
Publicado: (2016)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
por: Santerre Henriksen, Anne, et al.
Publicado: (2018)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Prevalence of hypervirulent and carbapenem-resistant Klebsiella pneumoniae under divergent evolutionary patterns
por: Tian, Dongxing, et al.
Publicado: (2022)

Emergence of colistin-resistant hypervirulent Klebsiella pneumoniae (CoR-HvKp) in China
por: Liu, Xiaoyu, et al.
Publicado: (2022)

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
por: Henriksen, Anne Santerre, et al.
Publicado: (2018)

Emergence of carbapenem-resistant Klebsiella pneumoniae harbouring bla (OXA-48)-like genes in China
por: Chen, Ying, et al.
Publicado: (2021)

Ceftobiprole for the treatment of pneumonia: a European perspective
por: Liapikou, Adamantia, et al.
Publicado: (2015)

Effective phage cocktail to combat the rising incidence of extensively drug-resistant Klebsiella pneumoniae sequence type 16
por: Martins, Willames M. B. S., et al.
Publicado: (2022)

A novel proteinaceous molecule produced by Lysinibacillus sp. OF-1 depends on the Ami oligopeptide transporter to kill Streptococcus pneumoniae
por: Hauge, Ingvild Hals, et al.
Publicado: (2023)

Simulated Comparison of a Bayesian Clinical Decision Support System Versus Standard of Care For Achieving Gentamicin Pharmacokinetic Targets in Neonates
por: Yu, Collin Z., et al.
Publicado: (2020)

Characterization of an NDM-5-producing hypervirulent Klebsiella pneumoniae sequence type 65 clone from a lung transplant recipient
por: Zhao, Jiankang, et al.
Publicado: (2021)

Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece
por: Galani, Irene, et al.
Publicado: (2012)

CpxR promotes the carbapenem antibiotic resistance of Klebsiella pneumoniae by directly regulating the expression and the dissemination of bla(KPC) on the IncFII conjugative plasmid
por: Liu, Zhiyuan, et al.
Publicado: (2023)

Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)
por: Baker, Jeffrey, et al.
Publicado: (2020)

A Novel Cecropin D-Derived Short Cationic Antimicrobial Peptide Exhibits Antibacterial Activity Against Wild-Type and Multidrug-Resistant Strains of Klebsiella pneumoniae and Pseudomonas aeruginosa
por: Ocampo-Ibáñez, Iván Darío, et al.
Publicado: (2020)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
por: Hamed, Kamal, et al.
Publicado: (2020)

1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020
por: Duncan, Leonard R, et al.
Publicado: (2021)

Comparative renal risk of long-term use of beta-lactams in combination with vancomycin across the continuum of care
por: Dolly, Lauren M., et al.
Publicado: (2023)

2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

LB2302. Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated Staphylococcus aureus (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE)
por: Holland, Thomas L, et al.
Publicado: (2022)

1595. Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019
por: Duncan, Leonard R, et al.
Publicado: (2020)

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)
por: Canton, Rafael, et al.
Publicado: (2022)

Micafungin in Premature and Non-premature Infants: A Systematic Review of 9 Clinical Trials
por: Manzoni, Paolo, et al.
Publicado: (2014)

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018)

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
por: Domachowske, Joseph B., et al.
Publicado: (2018)

Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study
por: Alter, Sherman J., et al.
Publicado: (2019)

Exploiting Homoplasy in Genome-Wide Association Studies to Enhance Identification of Antibiotic-Resistance Mutations in Bacterial Genomes
por: Lai, Yi-Pin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qot4b7diljlunpoc4555jf7k9l